Clinical Trials May Be Next Focus For Federal Health Care Prosecutors
Executive Summary
The conduct of clinical trials is likely to receive increased attention from federal health care prosecutors, Philadelphia Associate U.S. Attorney James Sheehan suggested June 17 at the Drug Information Association annual meeting in San Antonio
You may also be interested in...
“Whistleblower” Cases Reflect Evidence, Not Personality, Prosecutor Says
A federal prosecutor's decision to intervene in "whistleblower" cases is tied to the quality of the information, not the quality of the individual, Philadelphia Associate U.S. Attorney James Sheehan told the Drug Information Association annual meeting in San Antonio June 17
“Whistleblower” Cases Reflect Evidence, Not Personality, Prosecutor Says
A federal prosecutor's decision to intervene in "whistleblower" cases is tied to the quality of the information, not the quality of the individual, Philadelphia Associate U.S. Attorney James Sheehan told the Drug Information Association annual meeting in San Antonio June 17
Clinical Rx Trials Could Gain HCFA Financial Support Under Clinton Directive
Clinical trials of prescription drugs to treat conditions affecting the elderly could eventually receive funding from the Health Care Financing Administration under a June 7 directive from President Clinton.